ESC 2013:稳定性冠状动脉疾病指南

2013-09-04 MedSci MedSci原创

2013年9月1日,由Gilles Montalescot及UdoSechtem领导的工作小组在欧洲心脏病学会年会(ESC2013)上公布了最新的稳定性冠状动脉疾病指南。【全文阅读】本次更新的主要内容为:1.自2006年稳定性心绞痛管理与治疗指南出台之后,稳定性冠状动脉疾病(SCAD)的概念已经发生了变革,其范围更加广泛,除以冠状动脉血栓形成为主要临床表现的急性冠脉综合征外,很多CAD均属于SCA


2013年9月1日,由Gilles Montalescot及UdoSechtem领导的工作小组在欧洲心脏病学会年会(ESC2013)上公布了最新的稳定性冠状动脉疾病指南。【原文下载】
本次更新的主要内容为:
1.自2006年稳定性心绞痛管理与治疗指南出台之后,稳定性冠状动脉疾病(SCAD)的概念已经发生了变革,其范围更加广泛,除以冠状动脉血栓形成为主要临床表现的急性冠脉综合征外,很多CAD均属于SCAD的范畴。SCAD患者包括了以下几类患者:①稳定性心绞痛及伴有其他可能与冠脉疾病相关的症状如呼吸困难;②治疗后无症状但需要定期随访的伴有已知阻塞性或非阻塞性CAD;③自我首次报告症状但病情已处于慢性稳定状态。
2.新指南主要关注的是稳定性冠状动脉疾病的诊断检查与预后评估。很多检查能够同时提供诊断及预后信息,提示疾病的严重程度,并评估患者的预后。新指南的一个重要变化就是关注治疗策略对患者预后的意义。
3.对冠状动脉血运重建的作用进行了广泛的讨论,并就经皮冠状动脉介入治疗及冠状动脉旁路移植术对SCAD这一低危人群的预后价值进行了探讨和质疑。
4.新指南更加强调了验前概率的重要性,并根据现有证据更新了对验前概率的评估及其对诊断试验选择的影响。该修订版诊断及预后流程有助于简化临床决策过程,优化资源利用。
5.强调了导管室中对CAD进行生理评估的重要性,并提供了以诊断及治疗为目的的实践操作流程。
6.新指南在对SCAD进行诊断及预后评估时综合考虑动脉粥样硬化狭窄、微血管功能障碍及冠状动脉痉挛等多方因素。
7.注重生活方式干预与药物治疗,并提供了可行的干预选择。就药物治疗而言,指南介绍了目前常用的伊伐布雷定、尼可地尔、曲美他嗪和雷诺嗪等药物以及极具应用前景的心脏康复、流感疫苗接种及激素替代疗法等新选择。
8.对伴有动脉血压及心率下降的患者、女性、老年、合并糖尿病、慢性肾病以及有血运重建病史的各亚组人群进行了关注与深入分析。
 
原文下载
Task Force Members, Montalescot G, Sechtem U, Achenbach S.(The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org/guidelines.)2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology.Eur Heart J. 2013 Aug 30.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=6348, encodeId=54036348cf, content=挺好的信心,支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e9b66287, createdName=gulingling5142, createdTime=Fri Dec 06 14:35:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6312, encodeId=bdf36312b6, content=需要, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq6oFDfbfbCR2QaXr43JZleficjricO9bqaynTice57nB7xlLgg7tXtX5Y7RdTrC6pjWbuiaJ5RLVvib8w/132, createdBy=0c4390618, createdName=qingqingye, createdTime=Fri Nov 29 23:50:00 CST 2013, time=2013-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900418, encodeId=b9451900418a5, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 26 15:23:00 CST 2013, time=2013-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252857, encodeId=1cb3125285e2e, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Sep 06 07:23:00 CST 2013, time=2013-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625298, encodeId=c9711625298e5, content=<a href='/topic/show?id=ce70e5302f2' target=_blank style='color:#2F92EE;'>#稳定性冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75302, encryptionId=ce70e5302f2, topicName=稳定性冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8220733002, createdName=liuhuangbo, createdTime=Fri Sep 06 07:23:00 CST 2013, time=2013-09-06, status=1, ipAttribution=)]
    2013-12-06 gulingling5142

    挺好的信心,支持

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=6348, encodeId=54036348cf, content=挺好的信心,支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e9b66287, createdName=gulingling5142, createdTime=Fri Dec 06 14:35:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6312, encodeId=bdf36312b6, content=需要, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq6oFDfbfbCR2QaXr43JZleficjricO9bqaynTice57nB7xlLgg7tXtX5Y7RdTrC6pjWbuiaJ5RLVvib8w/132, createdBy=0c4390618, createdName=qingqingye, createdTime=Fri Nov 29 23:50:00 CST 2013, time=2013-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900418, encodeId=b9451900418a5, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 26 15:23:00 CST 2013, time=2013-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252857, encodeId=1cb3125285e2e, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Sep 06 07:23:00 CST 2013, time=2013-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625298, encodeId=c9711625298e5, content=<a href='/topic/show?id=ce70e5302f2' target=_blank style='color:#2F92EE;'>#稳定性冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75302, encryptionId=ce70e5302f2, topicName=稳定性冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8220733002, createdName=liuhuangbo, createdTime=Fri Sep 06 07:23:00 CST 2013, time=2013-09-06, status=1, ipAttribution=)]
    2013-11-29 qingqingye

    需要

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=6348, encodeId=54036348cf, content=挺好的信心,支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e9b66287, createdName=gulingling5142, createdTime=Fri Dec 06 14:35:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6312, encodeId=bdf36312b6, content=需要, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq6oFDfbfbCR2QaXr43JZleficjricO9bqaynTice57nB7xlLgg7tXtX5Y7RdTrC6pjWbuiaJ5RLVvib8w/132, createdBy=0c4390618, createdName=qingqingye, createdTime=Fri Nov 29 23:50:00 CST 2013, time=2013-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900418, encodeId=b9451900418a5, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 26 15:23:00 CST 2013, time=2013-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252857, encodeId=1cb3125285e2e, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Sep 06 07:23:00 CST 2013, time=2013-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625298, encodeId=c9711625298e5, content=<a href='/topic/show?id=ce70e5302f2' target=_blank style='color:#2F92EE;'>#稳定性冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75302, encryptionId=ce70e5302f2, topicName=稳定性冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8220733002, createdName=liuhuangbo, createdTime=Fri Sep 06 07:23:00 CST 2013, time=2013-09-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=6348, encodeId=54036348cf, content=挺好的信心,支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e9b66287, createdName=gulingling5142, createdTime=Fri Dec 06 14:35:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6312, encodeId=bdf36312b6, content=需要, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq6oFDfbfbCR2QaXr43JZleficjricO9bqaynTice57nB7xlLgg7tXtX5Y7RdTrC6pjWbuiaJ5RLVvib8w/132, createdBy=0c4390618, createdName=qingqingye, createdTime=Fri Nov 29 23:50:00 CST 2013, time=2013-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900418, encodeId=b9451900418a5, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 26 15:23:00 CST 2013, time=2013-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252857, encodeId=1cb3125285e2e, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Sep 06 07:23:00 CST 2013, time=2013-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625298, encodeId=c9711625298e5, content=<a href='/topic/show?id=ce70e5302f2' target=_blank style='color:#2F92EE;'>#稳定性冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75302, encryptionId=ce70e5302f2, topicName=稳定性冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8220733002, createdName=liuhuangbo, createdTime=Fri Sep 06 07:23:00 CST 2013, time=2013-09-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=6348, encodeId=54036348cf, content=挺好的信心,支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e9b66287, createdName=gulingling5142, createdTime=Fri Dec 06 14:35:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6312, encodeId=bdf36312b6, content=需要, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq6oFDfbfbCR2QaXr43JZleficjricO9bqaynTice57nB7xlLgg7tXtX5Y7RdTrC6pjWbuiaJ5RLVvib8w/132, createdBy=0c4390618, createdName=qingqingye, createdTime=Fri Nov 29 23:50:00 CST 2013, time=2013-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900418, encodeId=b9451900418a5, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 26 15:23:00 CST 2013, time=2013-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252857, encodeId=1cb3125285e2e, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Sep 06 07:23:00 CST 2013, time=2013-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625298, encodeId=c9711625298e5, content=<a href='/topic/show?id=ce70e5302f2' target=_blank style='color:#2F92EE;'>#稳定性冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75302, encryptionId=ce70e5302f2, topicName=稳定性冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8220733002, createdName=liuhuangbo, createdTime=Fri Sep 06 07:23:00 CST 2013, time=2013-09-06, status=1, ipAttribution=)]

相关资讯

ESC 2013:院外心脏骤停的生存率仅有7%

  2013 ESC年会上法国的Xavier Jouven教授及WulfranBougouin博士等人发表的研究表明,院外心脏骤停的生存率仅有7%。   心脏性猝死(SCD)是一个重要的公共卫生问题,每年会有超过400000人因心脏性猝死而死亡。其主要的病因是室性心动过速,常由急性缺血事件所触发,在既往有无心脏病的患者中均可发生。尽管在干预方面投入了很大的力量,但过去40年来心脏骤停的生存率仍然

ESC 2013:体力活动降低体格不佳男性心脏性猝死风险

  芬兰的JariLaukkanen及Magnus Hagnas等人在ESC 2013年会8月31日大会上发布的最新研究结果显示,体力活动能降低体格不佳男性心脏性猝死的发生风险。   Laukkanen博士指出,心脏性猝死(SCD)约占冠心病死亡的50%。其通常在出现症状后不久就发生,留给医生的有效医疗干预事件非常有限,且大多发生于院外或无任何预警信号,故找到识别SCD风险增高人群的办法将有望实

EHJ:他汀均可改善ACS预后

近日,在2013年欧洲心脏病学会年会上,有西班牙学者发表研究表明,即使ACS患者基线LDL-C水平不高,他汀治疗仍可获得明显的中期益处,相关论文发表在欧洲心脏杂志(EuroPean Heart Journal)上。 该研究为一单中心前瞻性观察性研究,为期16个月,观察对象为该中心出院诊断为ACS所有连续患者。患者的LDL-C水平按ESC指南分类(<70 

ESC 2013:血小板表面的CAR能确诊病毒性心肌炎所致的心律失常

  引言:心律失常可作为病毒感染所致心肌炎的唯一临床表现。但是,这类患者目前尚无很好的治疗策略。工作心肌细胞上存在柯萨奇病毒-腺病毒受体(CAR),CAR一方面会影响心肌细胞的电传导性,另一方面还可使病毒与心肌细胞相结合。近期研究发现,CAR还能存在于血小板,通过内吞不同颗粒(包括病毒)参与宿主防御反应。病毒性心肌炎的诊断通常较为困难,主要是依靠心内膜心肌活检(EMB)。但问题是并不是所有患者都能

ESC 2013:DPP-4抑制剂类糖尿病药物未增加心血管风险

近日,在欧洲心脏协会(ESC)年度会议上,研究人员详细陈述了过去两年针对16492例服用Onglyza和5380例服用Nesina的糖尿病患者的心血管风险研究结果。总体上讲,两项研究表明用于治疗2型糖尿病的二肽基肽酶-4(DPP-4)抑制剂类药物不会导致心脏病发作,但可能会因心脏不能充分泵血,引发心衰。同时,布利甘-妇女医院研究人员称心衰只是个例,还需进一步研究确认。因此,阿斯利康和百时美施贵宝宣

ESC 2013:他汀类药物可降低白内障风险50%

8月31日,ESC 2013大会上美国John B. Kostis教授公布的一项新研究显示,他汀类药物可使白内障发生率降低20%。在治疗疗程较长的年轻(40岁)人群中,他汀类药物能使白内障的发生风险降低50%。